Hereditary tyrosinaemia type I: From basics to progress in treatment

Annals of Medicine

Volumn 32, Issue 8, 2000, Pages 530-538

  Pitkänen, Sari T ^a   Salo, Matti K ^b   Heikinheimo, Markku ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

2 (2 nitro 4 trifluoromethylbenzoyl) 1; 3 cyclohexanedione; Fumarylaceroacerate hydrolase; Hepatocellular carcinoma; Hereditary tyrosinaemia typeI

Indexed keywords

4 HYDROXYPHENYLPYRUVATE DIOXYGENASE; 5 AMINOLEVULINATE SYNTHASE; ALPHA FETOPROTEIN; AMINOLEVULINIC ACID; CA 125 ANTIGEN; ENZYME INHIBITOR; FUMARIC ACID; FUMARYLACETOACETASE; HOMOCYSTEINE; METHIONINE; NITISINONE; OXYGENASE; PHENYLALANINE; PORPHOBILINOGEN; PORPHOBILINOGEN SYNTHASE; SUCCINYLACETONE; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER RISK; CHROMOSOME 15; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA EROSION; DRUG EFFICACY; ENZYME INHIBITION; GENE LOCATION; GENE MUTATION; GENE THERAPY; GENETIC LINKAGE; HUMAN; KIDNEY FAILURE; LIVER CANCER; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MOUSE; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PHOTOPHOBIA; PRIORITY JOURNAL; PROTEIN RESTRICTION; PRURITUS; REVIEW; THROMBOCYTOPENIA; TYROSINEMIA;

EID: 0033660129     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890008998832     Document Type: Review

References (91)

1. On the enzymic defect in hereditary tyrosinemia
2. Hypertyrosinemia
3. Tyrosinemia with plantar and palmar keratosis and keratitis
4. Tyrosine
5. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I)
6. Effects of succinylacetone on methyl alpha-D-glucoside uptake by the rat renal tubule
7. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-amino-levulinic acid dehydratase activity by succinylacetone
8. Biochemical studies on the enzymatic deficiencies in hereditary tyrosinemia
9. Type I tyrosinemia: Lack of immunologically detectable fumarylacetoactase enzyme protein in tissue and cell extracts
10. Hereditary tyrosinemias (type I): A new vista on tyrosine toxicity and cancer
11. Free radical generation during delta-aminolevulinic acid autoxidation: Induction by hemoglobin and connections with porphyrinpathies
12. Damage to rat liver mitochondria promoted by delta-aminolevulinic acid-generated reactive oxygen species: Connections with acute intermittent porphyria and lead-poisoning
13. Presence of type III collagen in guinea-pig dermal scar
14. Vitamin A-containing lipocytes and formation of type III collagen in liver injury
15. Stimulation of collagen synthesis in fibroblast cultures by superoxide
16. Tyrosine and its catabolites: From disease to cancer
17. The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion
18. Hepatocyte injury in tyrosinemia type I is induced by fumarylacetoacetate and is inhibited by caspase inhibitors
19. Complete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway
20. Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis
21. Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: Assignment of the gene to chromosome 15
22. Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity
23. Structural organization and analysis of the human fumarylacetoacetate hydrolase gene in tyrosinemia type I
24. Type I hereditary tyrosinemia. Evidence for molecular heterogenity and identification of a causal mutation in a French Canadian patient
25. Mutations of the fumarylaceto-acetate hydrolase gene in four patients with tyrosinemia, type I
26. A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I
27. Heterozygosity of an exon 12 splicing mutation and a W234X mutation in an American child with chronic tyrosinemia type I
28. Two missense mutations causing tyrosinemia type I with presence and absence of immunoreactive fumarylacetoacetase
29. Tyrosinemia type I: Complex spilcing defects and a missense mutation in the fumarylacetoacetase gene
30. Novel splice, missense and nonsense mutations in the fumarylacetoacetase gene causing tyrosinemia type I
31. Identification of a frequent pseudodeficiency mutation in the fumarylacetoacetase gene, with implications of diagnosis of tyrosinemia type I
32. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I
33. Two novel mutations involved in hereditary tyrosinemia type I
34. Hereditary tyrosinemia type I: Novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship
35. Six novel mutations involved in the fumarylacetoacetate hydrolase gene in patients with hereditary tyrosinemia type I
36. Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: Overview
37. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type I patients in Nortwestern Europe and Mediterranean countries
38. Hereditary tyrosinemia type I: Lack of correlation between clinical findings and amount of immunoreactive fumarylacetoacetase protein
39. Murine fumarylacetoacetate hydrolase (Fah) gene is disrupted by a neonatally lethal albino deletion that defines the hepatocyte-specific developmental regulation 1 (hsdr-1) locus
40. Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice
41. Rescue of mice homozygous for lethal albino deletions: Implications for an animal model for the human liver disease tyrosinemia type I
42. Metabolic studies in a mouse model of hepatorenal tyrosinemia: Absence of perinatal abnormalities
43. Ex vivo hepatic gene therapy of a mouse model of hereditary tyrosinemia type I
44. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinemia type I
45. Adenovirus-mediated gene therapy in mouse model of hereditary tyrosinemia type I
46. Hereditary tyrosinemia type I - An overview
47. Hereditary tyrosinemia in a French Canadian isolate
48. Genetic epidemiology of hereditary tyrosinemia in Quebec and the Saguenay-Lac-St Jean
49. Mutation analysis for prenatal diagnosis of hereditary tyrosinemia type I
50. Hereditary tyrosinemia type I: A new clinical classification with difference in prognosis on dietary treatment
51. Tyrosinemia type I and hyperthrophic obstructive cardiomyopathy
52. The occurence of hepatoma in the cronic form of hereditary tyrosinemia
53. Neurologic crises in hereditary tyrosinemia
54. Tyrosinemia type I - An update
55. The pre- and post-natal diagnosis of tyrosinemia type I and the detection of the carrier state by assay of fumarylacetoacetase
56. Deficient fumarylacetoactate fumarylhydrolase activity in lymphocytes and fibroblasts from patients with hereditary tyrosinemia
57. Prenatal diagnosis of hereditary tyrosinemia by determination of fumarylacetoacetase in cultured amniotic fluid cells
58. Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect
59. Self-induced correction of the genetic defect in tyrosinemia type I
60. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes
61. Alpha-1-fetoprotein measurement in blood spotted on paper: Discriminating test for hereditary tyrosinemia in neonatal mass screening
62. Pitfalls in the initial diagnosis of tyrosinemia: Three case reports and a review of the litterature
63. Tyrosinemia type I with normal levels of plasma tyrosine
64. Increased need for L-cysteine in hereditary tyrosinemia
65. Biochemical studies of a patient with hereditary hepatorenal tyrosinemia: Evidence for glutathione deficiency
66. Prenatal diagnosis of hereditary tyrosinemia: Measurement of succinylacetone in amniotic fluid
67. Stable isotope dilution analysis of succinylacetone using electron capture negative ion mass fragmentography: An accurate approach to the pre- and neonatal diagnosis of hereditary tyrosinemia type I
68. Fumarylacetoacetase activity in cultured and non-cultured chorionic villus cells, and assay in two high-risk pregnancies
69. Homotransplantation of the liver in a patient with hepatoma and hereditary tyrosinemia
70. Hereditary tyrosinemia type I (chronic form): Pathologic findings in the liver
71. Early liver transplantation is indicated for tyrosinemia type I
72. Liver transplantation for tyrosinemia. A review of 10 cases from university of Pittsburg
73. Liver transplantation in a 23-year-old tyrosinemia patient: Effects on the renal tubular dysfunction
74. Contribution of extrahepatic tissue to biochemical abnormalities in hereditary tyrosinemia type I: Study of three patients after liver transplantation
75. The effects of early treatment of hereditary tyrosinemia type I in by orthotopic liver transplantation
76. Liver transplantation for hereditary tyrosinemia: The Quebec experience
77. The nephropathy of type I tyrosinemia after liver transplantation
78. Treatment of hereditary tyrosinemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
79. Tyrosinemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione)
80. Structure, polymorphism, and novel repeated DNA elements revealed by a complete sequence of the human alpha-fetoprotein gene
81. Diagnosis and management of tyrosinemia type I
82. Treatment of tyrosinemia type I with an enzyme inhibitor (NTBC)
83. Plasma antioxidant capacity in two cases of tyrosinaemia type I: One case treated with NTBC
84. Tyrosinaemia - Treatment and outcome
85. Serum alpha-fetoprotein and its lectin reactivity in liver diseases: A review
86. Liver transplantation in type I tyrosinemia
87. A radioimunoassay using monoclonal antibody to monitor the course of epithelial ovaria cancer
88. Antigen detection by the monoclonal antibodies CA 19-9 and CA 125 in normal and tumor tissue and patients sera
89. Serum levels of oncofetal markers CA 125, CA 19-9 and alpha-fetoprotein in children with hereditary tyrosinemia type I
90. Gastrointestinal cancer-associated antigen in immunoperoxidase assay
91. Outcome of therapy of hereditary tyrosinemia